- Home
- J vs GMAB Comparison
J vs GMAB Comparison
Compare J & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- J
- GMAB
- Stock Information
- Founded
- J 1947
- GMAB 1999
- Country
- J United States
- GMAB Denmark
- Employees
- J N/A
- GMAB N/A
- Industry
- J Military/Government/Technical
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- J Industrials
- GMAB Health Care
- Exchange
- J Nasdaq
- GMAB Nasdaq
- Market Cap
- J 15.1B
- GMAB 13.7B
- IPO Year
- J N/A
- GMAB N/A
- Fundamental
- Price
- J $132.03
- GMAB $20.30
- Analyst Decision
- J Buy
- GMAB Buy
- Analyst Count
- J 8
- GMAB 8
- Target Price
- J $150.86
- GMAB $37.60
- AVG Volume (30 Days)
- J 651.4K
- GMAB 1.5M
- Earning Date
- J 08-05-2025
- GMAB 08-07-2025
- Dividend Yield
- J 0.97%
- GMAB N/A
- EPS Growth
- J N/A
- GMAB 276.80
- EPS
- J 3.66
- GMAB 18.36
- Revenue
- J $11,686,906,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- J N/A
- GMAB $747.74
- Revenue Next Year
- J $6.06
- GMAB $14.81
- P/E Ratio
- J $43.26
- GMAB $11.07
- Revenue Growth
- J 35.39
- GMAB 25.43
- 52 Week Low
- J $105.18
- GMAB $17.24
- 52 Week High
- J $149.05
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- J 63.47
- GMAB 39.68
- Support Level
- J $127.87
- GMAB $20.39
- Resistance Level
- J $133.91
- GMAB $21.08
- Average True Range (ATR)
- J 2.05
- GMAB 0.35
- MACD
- J 0.33
- GMAB -0.20
- Stochastic Oscillator
- J 82.51
- GMAB 2.63
About J Jacobs Solutions Inc.
Jacobs Solutions is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Solutions employs approximately 60,000 workers. The company generated $11.5 billion in revenue in fiscal 2024.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.